TY - JOUR
T1 - First-in-class angiotensin receptor neprilysin inhibitor in heart failure
AU - Vardeny, O.
AU - Tacheny, T.
AU - Solomon, S. D.
PY - 2013/10/1
Y1 - 2013/10/1
N2 - Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning.
AB - Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning.
UR - http://www.scopus.com/inward/record.url?scp=84884498780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884498780&partnerID=8YFLogxK
U2 - 10.1038/clpt.2013.146
DO - 10.1038/clpt.2013.146
M3 - Article
C2 - 23872864
AN - SCOPUS:84884498780
SN - 0009-9236
VL - 94
SP - 445
EP - 448
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -
